Debbie Rigby rounds up the latest in research news
This article summarises the currently available data on the clinical features of and treatment options
for COVID-19. The main therapies being used to treat the disease are antiviral drugs, chloroquine/hydroxychloroquine and respiratory therapy; however, there is no evidence for efficacy. Currently, quarantine is the only intervention that appears to be effective in decreasing the contagion rate.
Journal of Internal Medicine 2020.
Screening of frailty is being proposed in this article as a key tool to assist in the triage process for treatment of COVID-19 in older people. Frailty can capture the health status of an older person and is a predictor of multiple adverse outcomes. The authors recommend against the use of frailty screening tools as the sole component to ration access of older people to health care in the context of COVID-19.
Age and Ageing 2020.
A large analysis of nearly 100,000 patients hospitalised for COVID-10 has shown no evidence of benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.
Lancet, published 22 May 2020.
In a double-blind, randomised, placebo-controlled trial of intravenous remdesivir in adults hospitalised with COVID-19 with evidence of lower respiratory tract involvement, remdesivir was superior to placebo in shortening the time to recovery. The median recovery time in patients treated with remdesivir was 11 days compared 15 days among those who received placebo.
New Engl J Med, published 22 May 2020.